On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Takeda’s Pevonedistat Up for Discussion for 1st Legally Backed Sakigake Designation
July 19, 2021
- Lilly’s Selpercatinib, Rinvoq’s Eczema Use Up for PAFSC Review on July 30
July 19, 2021
- Japan Expands Supply of AstraZeneca’s COVID-19 Vaccine to Asian Nations
July 19, 2021
- New Pharma Industry Vision to Set Out Roles of Wholesalers: MHLW Director
July 16, 2021
- Snap Inspections at Generic Plants Conducted in 46 Prefectures, Results Due Out in August
July 16, 2021
- Japan to Lower Moderna Vaccine’s Minimum Age to 12
July 16, 2021
- MHLW Unmet Needs Council OKs Public Knowledge-Based Filings for 2 Antiemetics
July 15, 2021
- ICMRA Discussing Substitutes for Placebo-Controlled Trials of COVID Vaccines: MHLW
July 15, 2021
- Forxiga’s CKD Indication Up for PAFSC Review on July 28, Possible OK in August
July 15, 2021
- Chugai’s Antibody Cocktail Up for PAFSC Review on July 19, 4th COVID-19 Drug If Approved
July 13, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
July 9, 2021
- Japan PM “Watching Expert Discussions” on AstraZeneca Vaccine Use
July 9, 2021
- Japan OKs FY2022 Budget Guidelines, 660 Billion Yen Cap for Social Security Cost Rise
July 8, 2021
- MHLW Announces 1st Revision of Dyslipidemia Drug Development Guidelines in 30 Years
July 8, 2021
- Label Revisions Ordered for Myocarditis/Pericarditis Risks of Pfizer, Moderna’s COVID Vaccines
July 8, 2021
- MHLW’s COVID-19 Guide Recommends against Camostat after Trial Failures
July 7, 2021
- Health Minister Hints at Priority Vaccine Supply to Municipalities Making Headway
July 7, 2021
- MHLW Ups Ante for Regulatory Reviews of Jointly Developed Generics
July 7, 2021
- Leigh Syndrome Drug PTC743 Gets Orphan Status
July 6, 2021
- Draft Revision of MHLW’s Distribution Guidelines Stresses Compliance with Antitrust Act
July 5, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…